**Core tip:** The epidemiological knowledge of variations of etiology of chronic liver diseases (CLD) is crucial for health policy of resource allocation and for planning strategies of prevention and treatment. Our study, carried out in a large population from 1998 to 2014 period, shows that, in Northwest Italy, viral CLD decreased and CLD due to metabolic disorders remarkably increased. These results suggest the need to perform a strategy of rigorous education and counseling, in particular in overweight and obese subjects.

INTRODUCTION
============

The epidemiology of chronic liver diseases (CLD) in Italy is now changing due to the decreasing rate of viral hepatitis\[[@B1]\] and the increasing new epidemic of a wide spectrum of metabolic disorders like steatosis, non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH)\[[@B2]\]. The last three decades witnessed extensive diagnosis of the major hepatitis viruses, such as hepatitis C virus (HCV), hepatitis B virus (HBV) and hepatitis D virus (HDV) and their diffuse treatment with antiviral therapy. In addition, vaccination programs against HBV, which in Italy became mandatory since 1991, helped to achieve the complete immunization of newborn, teenagers and young adults\[[@B3],[@B4]\]. This active approach for HBV prevention was also effective against the risk of acquiring a superimposed HDV infection. As a result, Italy has become a country with a low (\< 0.3%) endemicity for HBV infection, and HDV infection is almost vanishing\[[@B3]\]. However, HCV infection alone, despite the lowest rate of infection occurring to date in young adults, remains at risk of spread among subjects with a lifestyle prone to high risk behaviours or undergoing invasive medical procedures.

Unfortunately, the amelioration of hygiene and social conditions, has been accompanied by a rapid change in eating habits of Italian people, with a diet richer in sugar and lipids compared to the past healthy Mediterranean regimen. Furthermore, overweight and obesity in children and adults have reached prevalence rate of 10%-15%\[[@B5]\]. Such figures, although lower compared to those reported in North America\[[@B6]\], are substantial. We are thus facing a significant change in the main causes of CLD compared to the recent past. Hence, the knowledge of the new etiological pattern of CLD has became very important in planning both the strategy of health policy and clinical recommendations for the next decades.

The Unit of Gastroenterology of Molinette Hospital represents the main facility in the Northwest of Italy (with a population of around 6 million people) among those dedicated to the management of liver diseases. Since, in this area, there are no updated data on the trend of the etiology of CLD, the aim of the present study was to address this issue over the period 1998-2014.

MATERIALS AND METHODS
=====================

A sample of charts of patients referred to by the general practitioners for hepatology reasons, from January 1998 to December 2014, was reviewed. In our outpatient facility, the medical personnel is organized in work teams that follow cohorts of patients with specific pathologies. The mean number of consultations is from 10000 to 12000 per year\[[@B7]\]. Patients were divided into three main cohorts: (1) with suspected or known chronic liver disease; (2) with suspected or known bowel diseases; and (3) with suspected or known diseases of the upper gastrointestinal tract. Consultations are usually assigned into "first" and "control" in order to check the number of incidental cases in comparison to prevalent cases. For the purpose of this study, only patients with the first consultation were included. We analyzed the triennial prevalence of different causes of liver disease during the periods 1998-2000, 2001-2003, 2004-2006 in order to detect early changes in etiological trends. The cohort 2012-2014 was included to confirm the previous trend also in recent years. Since in the period 2007-2012 the outpatient clinic changed location, part of the data have not been homogeneously collected, due to logistic problems. Hence, to avoid biases we excluded this period from the analysis.

The more prevalent indication for hepatology consultations was the increase in liver enzymes. The search for etiology included testing for HBV serological markers (hepatitis B surface antigen, antibodies to hepatitis B core antigen), HDV serological markers (antibodies to HDV, IgG and IgM), and HCV serological markers (antibodies to HCV). Viral replication was measured by testing serum HBV-DNA, HDV-RNA, or HCV-RNA, using quantitative assays mainly based on PCR techniques to amplify the target nucleic acid (*i.e*., COBAS TaqMan HBV and COBAS TaqMan HCV, Roche Diagnostics). We also collected a lifetime drinking history. The threshold for a risky alcohol consumption was set at 40 g/d for men or 20 g/d for women.

Autoimmune chronic hepatitis and cholestatic liver diseases were diagnosed on the basis of international standard criteria\[[@B8]-[@B11]\]. Organ- and non-organ-specific autoantibodies were tested at the dedicated laboratory: Anti-nuclear, anti-mitochondrial, anti-smooth muscle and anti-liver/kidney microsome type 1 autoantibodies. Autoantibodies were evaluated by indirect immunofluorescence on murine liver and kidney. IgA, IgG and IgM were detected with fluorescein isothiocyanate.

Hereditary hemocromatosis was diagnosed according to the presence of abnormal ferritin and saturated transferring serum values, genetic test, or liver histology. Wilson's disease was diagnosed on the basis of accepted international criteria\[[@B12],[@B13]\]. Patients without known causes of CLD but serum aminotransferases elevation, histological and/or ultrasound evidence of hepatic steatosis/steatohepatitis, were considered as suffering from NAFLD or NASH\[[@B14]\].

The study conformed to the guidelines of the 1975 Declaration of Helsinki and was approved by the local Hospital ethical committee. Data were managed with respect of patients' privacy.

Statistical analyses
--------------------

Since the patient records were not available in electronic format, assessments of the etiologies of the CLD were evaluated in a review of random samples from physical files. No formal power analysis was performed respect to a statistical comparison and the sample size was determined on the basis of resources available for in-depth review of the medical records. A mean sample of 900 medical records (in order to obtain approximately 100 patients per year) have been extracted according to an ordered sequence generated using a uniform distribution. For each patient with confirmed CLD, demographic, clinical, and etiological data were recorded. The change of (1) HCV; (2) HCV alone; (3) metabolic; and (4) metabolic alone, etiology during the analyzed periods (1998-2000, 2001-2003, 2004-2006, 2012-2014) was evaluated using logistic regression models, adjusting for age and sex. Potential effect modification by age (\< 50, ≥ 50 years) was evaluated in the logistic model including an interaction between the variables age and period.

RESULTS
=======

The features of the cohort included in the study are reported in Table [1](#T1){ref-type="table"}. The overall number of enrolled patients was 1163 (644 males, 55%), with a median age of 52 (interquartile range: 40-62). Of this cohort, 528 (45%) had positivity for anti-HCV (35% HCV-alone) and 85 (7%) for HBV (6% HBV-alone). Among the virus-free patients, 417 (36%) had metabolic disorders. The remaining group included patients with history of alcohol abuse, less prevalent causes of CLD or concomitant conditions.

###### 

Patients characteristics *n* (%)

  **Variable**        ***n* = 1163**
  ------------------- ----------------
  Age, median (IQR)   52 (40-62)
  Males               644 (55)
  Etiology            
  HCV                 528 (45)
  HCV alone           407 (35)
  Metabolic           557 (48)
  Metabolic alone     417 (36)
  HBV                 85 (7)
  HBV alone           67 (6)
  Period              
  1998-2000           295 (25)
  2001-2003           251 (22)
  2004-2006           336 (29)
  2012-2014           281 (24)

HBV: Hepatitis B virus; HCV: Hepatitis C virus.

To gain insight into the temporal trend of the etiological pattern of CLD, four periods (1998-2000, 2001-2003, 2004-2006, 2012-2014) were analyzed. Focusing on the main etiologies, in comparison to 1998-2000 (41% of HCV alone), a reduction in HCV-related cases was detected during the periods 2001-2003 (35% of HCV alone, OR = 0.75, 95%CI: 0.53-1.06), 2004-2006 (33% of HCV alone, OR = 0.70, 95%CI: 0.50-0.97) and 2012-2014 (31%, OR = 0.64, 95%CI: 0.46-0.91) (Table [2](#T2){ref-type="table"}). On the contrary, liver disease due to metabolic disorders increased from 31.2%, during the period 1998-2000, to 39% during the period 2004-2006 (OR = 1.37, 95%CI: 0.99-1.91) and 2012-2014 (41%, OR = 1.53, 95%CI: 1.09-2.16) (Table [3](#T3){ref-type="table"}).

###### 

Hepatitis C virus Etiology by period

  **Period**         **Patients, *n***   **HCV**    **HCV alone**                                               
  ------------------ ------------------- ---------- ------------------ ---------- ---------- ------------------ -------
  1998-2000 (Ref.)   295                 157 (53)   1                  \-         121 (41)   1                  \-
  2001-2003          251                 127 (51)   0.89 (0.63-1.24)   0.487      87 (35)    0.75 (0.53-1.06)   0.107
  2004-2006          336                 140 (42)   0.61 (0.45-0.84)   0.002      112 (33)   0.70 (0.50-0.97)   0.031
  2012-2014          281                 104 (37)   0.51 (0.36-0.71)   \< 0.001   87 (31)    0.64 (0.46-0.91)   0.012

ORs were estimated by a logistic regression model adjusting for age and gender. HCV: Hepatitis C virus.

###### 

Metabolic etiology by period

  **Period**         **Patients, *n***   **Metabolic**   **Metabolic alone**                                         
  ------------------ ------------------- --------------- --------------------- ------- ---------- ------------------ -------
  1998-2000 (Ref.)   295                 136 (46)        1                     \-      92 (31)    1                  \-
  2001-2003          251                 121 (48)        1.08 (0.77-1.51)      0.663   78 (31)    0.98 (0.68-1.41)   0.907
  2004-2006          336                 167 (50)        1.14 (0.83-1.56)      0.418   131 (39)   1.37 (0.99-1.91)   0.061
  2012-2014          281                 133 (47)        1.01 (0.73-1.41)      0.947   116 (41)   1.53 (1.09-2.16)   0.015

ORs were estimated by a logistic regression model adjusting for age and gender.

Stratifying by age groups, no significant differences were observed in CLD incidence due to HCV alone between younger patients (\< 50 years) and older ones (≥ 50 years) (*P =* 0.252) (Table [4](#T4){ref-type="table"}), whereas the incidence of metabolic causes alone during the period 2004-2006 and 2012-2014 in comparison to 1998-2000 tended to be higher in older patients (≥ 50 years) than in younger ones (from 29% to 44% and 42% in the former *vs* from 33% to 34% and 40% in the latter group; OR = 1.81 *vs* 0.97, OR= 1.86 *vs* 1.16, *P =* 0.058) (Table [5](#T5){ref-type="table"}).

###### 

Subgroup analysis hepatitis C virus etiology

  **Subgroup**   **Period**        **Patients, *n***   **HCV (interaction *P* = 0.407)**   **HCV alone (interaction *P* = 0.252)**             
  -------------- ----------------- ------------------- ----------------------------------- ----------------------------------------- --------- ------------------
  Age \< 50 yr   1998-2000 (Ref)   132                 68 (52)                             1                                         61 (46)   1
                 2001-2003         114                 53 (46)                             0.80 (0.48-1.32)                          35 (31)   0.51 (0.30-0.86)
                 2004-2006         155                 70 (45)                             0.74 (0.46-1.18)                          55 (35)   0.62 (0.38-1.00)
                 2012-2014         111                 45 (41)                             0.55 (0.32-0.93)                          37 (33)   0.52 (0.30-0.89)
  Age ≥ 50 yr    1998-2000 (Ref)   163                 89 (55)                             1                                         60 (37)   1
                 2001-2003         137                 74 (54)                             0.96 (0.61-1.52)                          52 (38)   1.03 (0.64-1.65)
                 2004-2006         181                 70 (39)                             0.51 (0.33-0.79)                          57 (31)   0.77 (0.49-1.20)
                 2012-2014         170                 59 (35)                             0.46 (0.30-0.72)                          50 (29)   0.75 (0.47-1.19)

ORs were estimated by a logistic model including an interaction between the variables age and period. HCV: Hepatitis C virus.

###### 

Subgroup analysis metabolic etiology

                                          **Metabolic (interaction *P* = 0.300)**   **Metabolic alone (interaction *P* = 0.058)**             
  -------------- ------------------ ----- ----------------------------------------- ----------------------------------------------- --------- ------------------
  Age \< 50 yr   1998-2000 (Ref.)   132   56 (42)                                   1                                               44 (33)   1
                 2001-2003          114   54 (47)                                   1.21 (0.73-2.00)                                41 (36)   1.10 (0.65-1.87)
                 2004-2006          155   64 (41)                                   0.93 (0.58-1.49)                                52 (34)   0.97 (0.59-1.59)
                 2012-2014          111   52 (47)                                   1.08 (0.64-1.82)                                44 (40)   1.16 (0.67-1.99)
  Age ≥ 50 yr    1998-2000 (Ref.)   163   80 (49)                                   1                                               48 (29)   1
                 2001-2003          137   67 (49)                                   0.98 (0.62-1.55)                                37 (27)   0.87 (0.52-1.44)
                 2004-2006          181   103 (57)                                  1.36 (0.89-2.08)                                79 (44)   1.81 (1.15-2.83)
                 2012-2014          170   81 (48)                                   0.97 (0.63-1.50)                                72 (42)   1.86 (1.18-2.94)

ORs were estimated by a logistic model including an interaction between the variables age and period.

DISCUSSION
==========

The asymptomatic nature of mild CLD impedes the accurate determination of its epidemiology. Hence, it is crucial, periodically, to perform studies aiming at defining detailed incidence and prevalence of liver diseases as well as their etiology.

The findings of our study show that in Northwest Italy, the incidence and prevalence of HCV infection decreased notably. This feature is supported by studies reporting a sharp decline in viral infections in hepatology settings more in Northern than in Central and Southern Italy. In a multicentre study including more than 6000 inpatients and outpatients, admitted for increase in liver enzymes in the year 2001, 62.6% had HCV alone, 9.2% HBV alone and about 13% non-viral causes. With regard to Northern Italy, HCV alone was reported in the 33.2% of cases, equivalent to our 33.3%, while NAFLD was diagnosed in the 34.2% of cases\[[@B1]\], similarly to 39% of our study in the period 2004-2006. Hence, the findings of our facility, that was not involved in the above reported study, independently confirm the changes in epidemiology of CLD of the same area. Quite different is the situation in Southern Italy, where results of the SCIROCCO Study Group for Liver Disease, have found that 62.9% of cases of CLD were HCV positive, 11.9% were HBV positive, 1.3% were HBV/HCV co-infected, 11.6% had an alcoholic liver disease and 10.1% had NAFLD\[[@B15]\]. Thus, in the South of Italy, viral infection still remains the most common etiology and the main cause for referral to centers dedicated to hepatology. These findings are similar to those obtained in a US population-based study, performed in Connecticut (New Haven County), Oregon (Multnomah) and California (Oakland) in the period 1999-2001, where HCV alone (42%) or in combination with alcoholic liver disease (22%) were the principal causes of CLD, followed by NASH for 9% and HBV for 3%\[[@B16]\].

Considering the general population, in Northern Italy, the Dionysos study, collecting data of 6917 inhabitants of 2 towns (Campogalliano and Cormons), reported that the overall prevalence of anti-HCV-positivity was 3.2%. When classified by age, the prevalence was rather low (\< 1%) in subjects younger than 40 years but it raised markedly in subjects older than 60 years reaching a value of 10%\[[@B17]\]. According to some studies, this trend is in keeping with the so-called "cohort-effect"\[[@B18]\]. For instance, La Torre et al\[[@B18]\] estimated the HCV infection trends in Italy during the years 1996-2006. A strong reduction in HCV infection was observed (-12.45%), with no differences according to gender (-12.23% in males and females -12.8% in females). When stratified by age, the incidence rate decreased significantly, from 2.02 (age \< 65 years) to 0.55 (age \> 65 years) per 100000, without differences among groups. Moreover, with the new treatments based on direct antiviral agents (DAAs), that directly inhibit HCV replication targeting different viral-encoded proteins, a further drop in the prevalence of HCV can be expected in the next years\[[@B19]\]. Currently, since the DAA treatment for HCV has been introduced in our region in January 2015, an impact in the reduction of HCV prevalence found in our cohort could be excluded. Whether immigration is affecting the hepatitis virus epidemiology in Italy remains to be clarified.

Tightly linked to obesity and metabolic syndrome, NAFLD is emerging as potentially the overriding liver disease of the near future\[[@B20]\]. In our study there was an increase in rate of diagnosis of NAFLD. Although the latter was present in all cohorts, it was significantly higher in older than in younger subjects. Considering that an Italian multicentre cross-sectional study has shown that 23% of cases of hepatocellular carcinoma (HCC) occurred in virus-free patients with an increasing prevalence in the elderly, the issue of the age needs to be highlighted. Surveillance resulted an independent predictor for either single HCCs less than 2 cm or HCCs meeting the Milan criteria detection\[[@B21]\]. Moreover, in a cohort of US veterans, NAFLD and metabolic syndrome resulted the principal risk factors of 13% of patients with HCC without signs of cirrhosis\[[@B22]\]. Thus, the strict surveillance of these type of patients, in particular in elderly, is mandatory. This is more relevant considering that almost half of NAFLD patients have normal liver enzyme levels\[[@B2]\].

As part of the prevention program, an important role is played by behavior therapy for NAFLD. This is supported by previous observational studies\[[@B23],[@B24]\] and finally by a more recent randomized controlled trial\[[@B25]\]. In the near future, therapeutic and behavior interventions might be supported by new technologies, such as smartphone applications and web-based platforms in order to permit an interactive engagement between patients and physicians\[[@B26]\].

In contrast with several studies conducted in general populations or in specific cohorts (for example blood donors) with short period analysis, our study evaluated the incidence of the main etiologies in a hepatology setting during a long period. This could be important for health policy of resource allocation. The health sector is characterized by vast demand and a lack of funds due to budget constraints. Prioritization is therefore necessary. Updating disease burden data is thus crucial in developing policy and prevention strategies, prioritizing research and appropriately allocating resources.

Some limitations of the present study have to be recognized. Estimates resulting from our outpatient clinic does not represent the general population. Nevertheless, data sources were critically assessed to avoid under- or over-estimation and to make sure that the results were consistent with general Italian population epidemiology\[[@B18]\]. The potential heterogeneity in collecting data is limited both by the fact that, in our outpatient clinic\[[@B7]\], all authors follow International Guidelines and that data were not collected in an outpatient clinic dedicated to a specific etiology (for example, exclusive for NASH or for viral hepatitis) but in a general hepatology one. As the primary aim of our study was the definition of the epidemiologic pattern of these diseases over time, no data regarding CLD stages are provided. Another limitation is the lack of data in the period 2007-2012, due to the logistic problems above described.

In conclusion, our study carried out in a large population shows that, in Northwest Italy, there is a trend towards a decline in viral CLD and a relevant increase in liver diseases due to metabolic disorders. These results suggest the need for a strategy of rigorous counseling in the whole population, and particularly, in subjects with metabolic disorders.
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Background
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The epidemiology of chronic liver diseases (CLD) in Italy is now changing due to the decreasing rate of viral hepatitis and the increasing new epidemic of a wide spectrum of metabolic disorders like steatosis, non-alcoholic fatty liver disease and steatohepatitis. Since, in North-West Italy, there are no updated data on the trend of the etiology of CLD, the aim of the present study was to address this issue over the period 1998-2014.
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The epidemiological knowledge of variations of etiology of CLD is crucial for health policy of resource allocation and for planning strategies of prevention and treatment.
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The present study included 1163 patients with CLD. Of them, 528 (45%) had positivity for hepatitis C virus (HCV) and 85 (7%) for hepatitis B virus. Among the virus-free patients, 417 (36%) had metabolic disorders whereas the remaining had history of alcohol abuse, less prevalent causes of CLD or concomitant conditions. In comparison to 1998-2000 (41%), a reduction of HCV alone-related cases was detected during the periods 2001-2003 (35%, OR = 0.75, 95%CI: 0.53-1.06), 2004-2006 (33%, OR = 0.70, 95%CI: 0.50-0.97) and 2012-2014 (31%, OR = 0.64, 95%CI: 0.46-0.91). On the contrary, in comparison to 1998-2000 (31%), metabolic-alone disorders increased in the period 2004-2006 (39%, OR = 1.37, 95%CI: 0.99-1.91) and 2012-2014 (41%, OR = 1.53, 95%CI: 1.09-2.16).
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The study presented, carried out in a large population from 1998 to 2014 period, shows that, in Northwest Italy, viral CLD decreased and CLD due to metabolic disorders remarkably increased. These results suggest the need to perform a strategy of rigorous education and counseling, in particular in overweight and obese subjects.
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